Description
BEAT BioTherapeutics is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. BEATBio holds worldwide rights to this technology and its UW founders are recognized experts in cardiovascular biology, muscle physiology and bioengineering.
Team Members
Michael Kranda
CEO
Gregory Mahairas
President & Chief Scientific Officer
Sam Teichman
Chief Medical Officer
Gallery
